A Phase 1, Randomized, Open-Label, Parallel Group, Single-Dose Study To Compare The Pharmacokinetics And Safety Of The Auto-Injector And Pre-Filled Syringe Of Ct-P17, A Proposed, Higher Concentration Biosimilar (100 Mg/Ml) Adalimumab, In Healthy Subjects